But overdose fluorine can cause skeletal damage, which lesion fairly complicated.There are only osteosclerosis, ossifying around the bone, but osteomalacia, osteoporosis.

但过量会引起骼的损伤,其病变较复杂,既有硬化、周化,又有软化、质疏松。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调节剂，为预防绝经后质疏松症药物。

But overdose fluorine can cause skeletal damage, which lesion fairly complicated.There are only osteosclerosis, ossifying around the bone, but osteomalacia, osteoporosis.

但过量会引起骼的损伤,其病变较复杂,既有硬化、周化,又有软化、质疏松。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌体调剂，为预防绝经后质疏松症药物。

But overdose fluorine can cause skeletal damage, which lesion fairly complicated.There are only osteosclerosis, ossifying around the bone, but osteomalacia, osteoporosis.

但过量会引起骼的损伤,其变较复杂,既有硬、周,又有软、质疏松。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调节剂，为预防绝经后质疏松症药物。

But overdose fluorine can cause skeletal damage, which lesion fairly complicated.There are only osteosclerosis, ossifying around the bone, but osteomalacia, osteoporosis.

但过量会引起骨骼的损伤,其病变较复杂,既有骨硬化、骨周化骨,又有骨软化、骨质疏松。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性受体调剂，为预防绝经后骨质疏松症药物。

But overdose fluorine can cause skeletal damage, which lesion fairly complicated.There are only osteosclerosis, ossifying around the bone, but osteomalacia, osteoporosis.

但过量会引起骼损伤,其病变较复杂,既有硬、,又有软、质疏松。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调节剂，为预防绝经后质疏松症药物。

But overdose fluorine can cause skeletal damage, which lesion fairly complicated.There are only osteosclerosis, ossifying around the bone, but osteomalacia, osteoporosis.

但过量会引起骼的损伤,其病变较复杂,既有硬化、周化,又有软化、疏松。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调节剂，为预防绝经后疏松症药。

But overdose fluorine can cause skeletal damage, which lesion fairly complicated.There are only osteosclerosis, ossifying around the bone, but osteomalacia, osteoporosis.

但过量会引起骼的损伤,其变较复杂,既有硬、周,又有软、质疏松。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调节剂，为预防绝经后质疏松症药物。

But overdose fluorine can cause skeletal damage, which lesion fairly complicated.There are only osteosclerosis, ossifying around the bone, but osteomalacia, osteoporosis.

但过量会引起骼损伤,其病变较复杂,既有硬、周,有软、质疏松。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调节剂，为预防绝经后质疏松症药物。

But overdose fluorine can cause skeletal damage, which lesion fairly complicated.There are only osteosclerosis, ossifying around the bone, but osteomalacia, osteoporosis.

但过量会引起骼的损伤,其病变较复杂,有硬化、周化,又有软化、质疏松。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调节剂，为预防绝经后质疏松症药物。